Special Issue "Prostate Cancer: Past, Present, and Future"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 15 August 2019
Prof. Ajay Pratap Singh
Department of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USADepartment of Molecular Biology and Biochemistry, College of Medicine, University of South Alabama, Mobile, AL 36688, USA
Website | E-Mail
Interests: molecular mechanisms involved in cancer progression and chemoresistance; cancer progression and metastasis; therapeutic resistance in cancer; tumor–stromal interactions; molecular bases of cancer health disparities; MicroRNAs in cancer; molecular diagnosis, prognosis, and sub-classification of cancer; natural products as cancer prevention and therapy agents
This Special Issue of the Cancers (2017 Impact Factor: 5.326) will cover all aspects of prostate cancer, which is the most common non-cutaneous malignancy among men, with nearly 1.3 million new cases diagnosed globally in 2018. The highest rates of prostate cancer are noticed in developed countries, and age-adjusted incident rates have increased in recent times due to increased awareness and the availability of prostate-specific antigen (PSA) screening tests. While the use of PSA as a screening biomarker is debatable, prostate cancer undoubtedly is an important health issue that places a significant economic burden on the society. More notably, prostate cancer disproportionately affects men of certain racial/ethnic groups, especially those belonging to a lower socioeconomic status. The highest incidence and mortality rates of prostate cancer are observed among men of African origin, followed by non-Hispanic whites, Hispanics, and Asians/Pacific Islanders. Years of research has tremendously improved prostate cancer management and continues to improve our understanding of the causes and mechanisms of prostate cancer initiation, progression, therapy resistance, and associated health disparities. Evidence continues to grow suggesting genetic and phenotypic diversity of prostate cancer. Resulting insights have emphasized the development of newer screening and diagnostic assays that can not only discriminate between benign and cancerous diseases but are also able to classify them into indolent and potentially aggressive types. New advanced treatment approaches and therapeutic modalities for prostate cancer have also been developed, while several others are being currently evaluated in preclinical or clinical trials. Although the progress thus far in prostate cancer biology and clinical management has been impressive, many gaps in our knowledge still remain. This Special Issue intends to publish emerging data, expert opinions, and reviews to add to the growing knowledge base, and to derive meaningful interpretations from available research and clinical insights in scientific literature.
A broad range of studies on prostate cancer (research, clinical, outreach, and public health) will be considered for inclusion in this Special Issue. We encourage you to submit original, empirical studies as well as systematic reviews or meta-analyses. Short reports and methodological papers will also be considered. Especially, we encourage the submission of interdisciplinary work and multi-country collaborative research.
Prof. Ajay Pratap Singh
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Prostate cancer
- Cancer health disparities
- Molecular pathogenesis
- Tumor microenvironment
- Prevention and control